Senti Biosciences, Inc. (SNTI)

Senti Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020
Cash & Equivalents	39.45	60.99	59.29	31.03
Short-Term Investments	0	40.94	0	0
Cash & Cash Equivalents	39.45	101.93	59.29	31.03
Cash Growth	-61.30%	71.91%	91.05%	-
Receivables	0.11	0.63	0.48	0.09
Other Current Assets	31.64	0.02	0.42	0.59
Total Current Assets	71.2	102.58	60.19	31.71
Property, Plant & Equipment	41.61	69.78	33.08	16.14
Other Long-Term Assets	6.67	8.43	3.43	0.5
Total Long-Term Assets	48.28	78.21	36.51	16.64
Total Assets	119.48	180.79	96.7	48.35
Accounts Payable	1.25	1.37	5.19	0.91
Deferred Revenue	0.99	0.8	1.83	0
Current Debt	4.13	1.99	1.74	1.52
Other Current Liabilities	6.31	13.9	5.78	2.43
Total Current Liabilities	12.67	18.05	14.54	4.87
Long-Term Debt	33.54	35.1	20.99	12.53
Other Long-Term Liabilities	6.36	0.37	0.8	0
Total Long-Term Liabilities	39.9	35.48	21.78	12.53
Total Liabilities	52.57	53.53	36.33	17.4
Total Debt	37.67	37.09	22.73	14.05
Debt Growth	1.55%	63.17%	61.80%	-
Retained Earnings	-244.34	-173.29	-115.08	-59.76
Comprehensive Income	0	0	0	0
Shareholders' Equity	66.91	127.26	-111.46	-58.71
Net Cash / Debt	1.78	64.84	36.56	16.99
Net Cash / Debt Growth	-97.25%	77.35%	115.25%	-
Net Cash Per Share	0.04	2.48	12.55	1.23
Working Capital	58.53	84.53	45.65	26.84
Book Value Per Share	1.51	4.87	-38.27	-4.24

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).